The Retrospective Study of Second‐line Chemotherapy in Ovarian Cancer

Abstract

Objective: To evaluate the efficacy of Second‐line Chemotherapy for ovarian cancer not from short term efficacy but from the survival rate. Patients and Methods: Eighty‐seven patients with epitherial ovarian cancer treated with Second‐line chemotherapy from 1993 were examined retrospectively. All the patients were treated with platinum as first line chemotherapy (≥ 3 courses). Paclitaxel was used for Second‐line Chemotherapy in 25 patients. The Kaplan‐Meier Method and Log‐Rank Test were carried out for the cumulative survival rate and analysis. Results: The Median Survival Time of all patients after Second‐line Chemotherapy was 23.6 months. Any significant difference in the survival rate was recognized only by the histological diagnosis (p < 0.0001). There was no significant difference in the survival rates whether patients were treated with paclitaxel as second line chemotherapy or not (p = 0.1915). The disease free survival period of the Second Look Laparotomy (SLL) negative group (23.9 months) is longer than that of SLL positive group (6.2 months). Conclusions: The survival rate after Second‐line Chemotherapy was influenced only by histological diagnosis. ACTA OBST GYNAEC JPN Vol. 54, No. 9, pp. 1429–1436, 2002